New Insights into the Implication of Epigenetic Alterations in the EMT of Triple Negative Breast Cancer
- PMID: 31003528
- PMCID: PMC6521131
- DOI: 10.3390/cancers11040559
New Insights into the Implication of Epigenetic Alterations in the EMT of Triple Negative Breast Cancer
Abstract
Breast cancer is the most common cancer and leading cause of cancer death among women worldwide, encompassing a wide heterogeneity of subtypes with different clinical features. During the last two decades, the use of targeted therapies has emerged in clinical research in order to increase treatment efficiency, improve prognosis and reduce recurrence. However, the triple negative breast cancer (TNBC) subtype remains a clinical challenge, with poor prognosis since no therapeutic targets have been identified. This aggressive breast cancer entity lacks expression of oestrogen receptor (ER) and progesterone receptor (PR), and it does not overexpress human epidermal growth factor receptor 2 (HER2). The major reason for TNBC poor prognosis is early therapeutic escape from conventional treatments, leading to aggressive metastatic relapse. Metastases occur after an epithelial-mesenchymal transition EMT of epithelial cells, allowing them to break free from the primary tumour site and to colonize distant organs. Cancer-associated EMT consists not only of acquired migration and invasion ability, but involves complex and comprehensive reprogramming, including changes in metabolism, expression levels and epigenetic. Recently, many studies have considered epigenetic alterations as the primary initiator of cancer development and metastasis. This review builds a picture of the epigenetic modifications implicated in the EMT of breast cancer. It focuses on TNBC and allows comparisons with other subtypes. It emphasizes the role of the main epigenetic modifications lncRNAs, miRNAs, histone and DNA- modifications in tumour invasion and appearance of metastases. These epigenetic alterations can be considered biomarkers representing potential diagnostic and prognostic factors in order to define a global metastatic signature for TNBC.
Keywords: DNA methylation; epigenetic modifications; epithelial-mesenchymal transition EMT; histone modifications; long non-coding RNAs LncRNAs; metastasis; miRNAs; triple negative breast cancer TNBC.
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Epigenetic Alterations in Triple-Negative Breast Cancer-The Critical Role of Extracellular Matrix.Cancers (Basel). 2021 Feb 9;13(4):713. doi: 10.3390/cancers13040713. Cancers (Basel). 2021. PMID: 33572395 Free PMC article. Review.
-
Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.J Exp Clin Cancer Res. 2018 Dec 14;37(1):314. doi: 10.1186/s13046-018-0988-8. J Exp Clin Cancer Res. 2018. PMID: 30547810 Free PMC article.
-
Epigenetics of Triple-Negative Breast Cancer via Natural Compounds.Curr Med Chem. 2022 Mar 4;29(8):1436-1458. doi: 10.2174/0929867328666210707165530. Curr Med Chem. 2022. PMID: 34238140
-
Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.Clin Epigenetics. 2018 Jun 27;10:88. doi: 10.1186/s13148-018-0514-z. eCollection 2018. Clin Epigenetics. 2018. PMID: 29983835 Free PMC article. Review.
-
Triple negative breast cancer: looking for the missing link between biology and treatments.Oncotarget. 2015 Sep 29;6(29):26560-74. doi: 10.18632/oncotarget.5306. Oncotarget. 2015. PMID: 26387133 Free PMC article. Review.
Cited by
-
LncRNA SOX9-AS1 triggers a transcriptional program involved in lipid metabolic reprogramming, cell migration and invasion in triple-negative breast cancer.Sci Rep. 2024 Jan 17;14(1):1483. doi: 10.1038/s41598-024-51947-2. Sci Rep. 2024. PMID: 38233470 Free PMC article.
-
Polyphenol-Enriched Blueberry Preparation Controls Breast Cancer Stem Cells by Targeting FOXO1 and miR-145.Molecules. 2021 Jul 17;26(14):4330. doi: 10.3390/molecules26144330. Molecules. 2021. PMID: 34299605 Free PMC article.
-
(-)-Kusunokinin as a Potential Aldose Reductase Inhibitor: Equivalency Observed via AKR1B1 Dynamics Simulation.ACS Omega. 2020 Dec 21;6(1):606-614. doi: 10.1021/acsomega.0c05102. eCollection 2021 Jan 12. ACS Omega. 2020. PMID: 33458512 Free PMC article.
-
Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis.Front Oncol. 2022 Aug 1;12:940171. doi: 10.3389/fonc.2022.940171. eCollection 2022. Front Oncol. 2022. PMID: 35978823 Free PMC article.
-
DCST1-AS1 Promotes TGF-β-Induced Epithelial-Mesenchymal Transition and Enhances Chemoresistance in Triple-Negative Breast Cancer Cells via ANXA1.Front Oncol. 2020 Mar 12;10:280. doi: 10.3389/fonc.2020.00280. eCollection 2020. Front Oncol. 2020. PMID: 32226772 Free PMC article.
References
-
- Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA. 2001;98:10869–10874. doi: 10.1073/pnas.191367098. - DOI - PMC - PubMed
-
- He M.Y., Rancoule C., Rehailia-Blanchard A., Espenel S., Trone J.-C., Bernichon E., Guillaume E., Vallard A., Magné N. Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies. Crit. Rev. Oncol. Hematol. 2018;131:96–101. doi: 10.1016/j.critrevonc.2018.09.004. - DOI - PubMed
-
- Neelakantan D., Zhou H., Oliphant M.U.J., Zhang X., Simon L.M., Henke D.M., Shaw C.A., Wu M.-F., Hilsenbeck S.G., White L.D., et al. EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat. Commun. 2017;8:15773. doi: 10.1038/ncomms15773. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous